FDA 483 - Biocon Biologics Limited

An FDA inspection of Biocon Biologics Limited revealed significant deficiencies across its aseptic manufacturing operations, laboratory controls, and data management systems. Issues included inadequate validation of aseptic processes, failure to follow sterile procedures, compromised data integrity, and insufficient investigations into discrepancies. These findings indicate a high risk to the quality and sterility of drug products.